Search results
Showing 61 to 75 of 168 results for acute heart failure
This guideline covers care and treatment for adults (aged 18 and over) with type 1 diabetes. It includes advice on diagnosis, education and support, blood glucose management, cardiovascular risk, and identifying and managing long-term complications.
Optimising Medication in patients with Chronic Heart Failure
management of patients with heart failure (HF) in primary care. Using a virtual clinic model, 872 patients on GP...
Intravenous fluid therapy in children and young people in hospital (NG29)
This guideline covers general principles for managing intravenous (IV) fluids for children and young people under 16 years, including assessing fluid and electrolyte status and prescribing IV fluid therapy. It applies to a range of conditions and different settings. It does not include recommendations relating to specific conditions. This guideline represents a major opportunity to improve patient safety for children and young people having IV fluid therapy in hospital.
Venous thromboembolic diseases: diagnosis, management and thrombophilia testing (NG158)
This guideline covers diagnosing and managing venous thromboembolic diseases in adults. It aims to support rapid diagnosis and effective treatment for people who develop deep vein thrombosis (DVT) or pulmonary embolism (PE). It also covers testing for conditions that can make a DVT or PE more likely, such as thrombophilia (a blood clotting disorder) and cancer.
Evidence-based recommendations on electrical stimulation to improve muscle strength in chronic respiratory conditions, chronic heart failure and chronic kidney disease. This involves delivering electrical impulses to weakened muscles using electrodes placed on the skin.
View recommendations for IPG677Show all sections
Nirmatrelvir plus ritonavir, sotrovimab and tocilizumab for treating COVID-19 (TA878)
Evidence-based recommendations on nirmatrelvir plus ritonavir (Paxlovid), sotrovimab (Xevudy) and tocilizumab (RoActemra) for treating COVID-19.
RespiraSense for continuously monitoring respiratory rate (MIB299)
NICE has developed a medtech innovation briefing (MIB) on RespiraSense for continuously monitoring respiratory rate .
Evidence-based recommendations on dabigatran etexilate (Pradaxa) for preventing stroke and systemic embolism in adults with non-valvular atrial fibrillation.
Visensia for early detection of deteriorating vital signs in adults in hospital (MIB36)
NICE has developed a medtech innovation briefing (MIB) on Visensia for early detection of deteriorating vital signs in adults in hospital
EarlySense for heart and respiratory monitoring and predicting patient deterioration (MIB49)
NICE has developed a medtech innovation briefing (MIB) on EarlySense for heart and respiratory monitoring and predicting patient deterioration
conditions, chronic heart failure and chronic kidney disease shows no major safety concerns. For people who are having an...
This quality standard covers road-traffic-related air pollution and its impact on health. It describes high-quality actions in priority areas for improvement.
View quality statements for QS181Show all sections
Sections for QS181
- Quality statements
- Quality statement 1: Strategic plans
- Quality statement 2: Planning applications
- Quality statement 3: Reducing emissions from public sector vehicle fleets
- Quality statement 4: Advice for people with chronic respiratory or cardiovascular conditions
- Update information
- About this quality standard
This quality standard covers assessing and managing renal and ureteric stones in children, young people and adults. It describes high-quality care in priority areas for improvement.
Evidence-based recommendations on infliximab (Remicade, Inflectra or Remsima), adalimumab (Humira) and golimumab (Simponi) for treating moderate to severe ulcerative colitis in adults, and on infliximab for treating severe active ulcerative colitis in children and young people of 6–17 years.
This guideline covers preventing and managing foot problems in children, young people and adults with diabetes. It aims to reduce variation in practice, including antibiotic prescribing for diabetic foot infections.